Dr. Dang is principal scientist at Nitrome Biosciences where he worked with the assay development team to isolate enzymes (Nitrases) from native tissues. He is an innovative scientist with significant accomplishments in applying multidisciplinary approaches to develop therapeutics by establishing models for pain, aging, neuroinflammation and neurodegenerative diseases. He now leads the Cell Biology and in vivo Biology groups to investigate the involvement of Nitrases in health and diseases. Prior to joining Nitrome, Vu was project leader for internal research and development programs at NeuCyte.
At Alkahest, Vu developed cellular assays to validate the rejuvenating and aging factors in plasma and plasma fractions. His work contributed to patent filing and development of candidates currently in clinical trials. He also developed and implemented assays to screen for therapeutic molecules for multiple sclerosis and pain management at Teva. At iPierian, he was instrumental in the development of IPN007, an antibody for which BMS acquired iPierian and is currently owned by Biogen and in pivotal clinical trials for Progressive Supranuclear Palsy and Phase 2 trial for Alzheimer’s disease. Vu received his Ph. D. in physiology and pharmacology at Oregon Health & Sciences University and BA in biology at University of Portland.